ClinicalTrials.gg
CompletedNCT03727802Updated Oct 23, 2023Results posted

Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

A Phase 1 interventional study of TRK-250 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Toray Industries, Inc. Completed at 11 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Toray Industries, Inc · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
125th of 188
34 · median 61
Started
2018
with 14 others
Phase 1
39 of 236
3 open now
Registered
131st of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 125th largest by enrollment of the 188 interventional ones that give a count, is one of 15 that started in 2018, is one of 39 in phase 1, and was the 131st registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level. This study is a double-blind, randomized, placebo-controlled Phase I study. The primary objective of the study is to assess the safety and tolerability of single and multiple inhaled doses of TRK-250 in subjects with idiopathic pulmonary fibrosis (IPF).

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • TRK-250
  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical, radiographic, and histologic features consistent with the diagnosis of IPF
  • SpO2 ≥90% at rest by pulse oximetry while breathing ambient air.
  • FVC ≥50% of predicted.
  • ≥50% of predicted.
  • Ratio of FEV1 to FVC ≥0.7.
  • DLCO corrected for 30% to 79% of predicted, inclusive.

Exclusion criteria

Exclusion Criteria:

  • History of acute exacerbation of IPF or respiratory tract infection within 3 months prior to Screening.
  • Planned surgery during the study.
  • History of malignant tumor within 5 years prior to Screening.
  • History of emphysema or respiratory diseases (other than IPF).
  • Other known causes of interstitial lung disease (eg, drug toxicities, environmental exposures, connective tissue diseases).
  • End-stage fibrotic disease expected to require organ transplantation within 6 months.
  • Taking a systemic , cytotoxic therapy, vasodilator therapy for pulmonary hypertension, or unapproved treatment for IPF within 4 weeks prior to Screening. (Treatment with pirfenidone or nintedanib, though not both concurrently, is permitted, provided that the subject has been on a stable dose for at least 4 weeks prior to Screening and it is anticipated the dose will remain unchanged throughout enrollment.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    TRK-250

    Drug: TRK-250

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugTRK-250

    single and multiple doses (4 weeks)

  • DrugPlacebo

    single and multiple doses (4 weeks)

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events

    Number of patients reporting Adverse Events Number of patients by severity reporting Adverse Events

    Time frame: Up to 14 days after last dose

07

Results

Posted Oct 23, 2023

Participant flow

A total of 34 subjects were randomized to treatment, with 16 subjects in Part A and 18 subjects in Part B.

Participant flow — Overall Study
MilestonePartA:TRK-250 2mgPartA:TRK-250 10mgPartA:TRK-250 30mgPartA:TRK-250 60mgPartA:Pooled PlaceboPartB:TRK-250 10mgPartB:TRK-250 30mgPartB:TRK-250 60mgPartB:Pooled Placebo
Started333344446
Completed333344435
Not completed000000011

Outcome measures

PrimaryIncidence and Severity of Adverse Events

Number of patients reporting Adverse Events Number of patients by severity reporting Adverse Events

Time frame:
Up to 14 days after last dose
Reported as:
Count of participants · Participants
Incidence and Severity of Adverse Events
ParticipantsPartA:TRK-250 2mgPartA:TRK-250 10mgPartA:TRK-250 30mgPartA:TRK-250 60mgPartA:Pooled PlaceboPartB:TRK-250 10mgPartB:TRK-250 30mgPartB:TRK-250 60mgPartB:Pooled Placebo
Subjects with AEs103213233
Mild(Severity)002112103
Moderate(Severity)101101120
Severe(Severity)000000010

Adverse events

Collected over Up to 14 days after last dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PartA:TRK-250 2mg0/3 (0%)0/3 (0%)1/3 (33.3%)
PartA:TRK-250 10mg0/3 (0%)0/3 (0%)0/3 (0%)
PartA:TRK-250 30mg0/3 (0%)0/3 (0%)3/3 (100%)
PartA:TRK-250 60mg0/3 (0%)0/3 (0%)2/3 (66.7%)
PartA:Pooled Placebo0/4 (0%)0/4 (0%)1/4 (25%)
PartB:TRK-250 10mg0/4 (0%)0/4 (0%)3/4 (75%)
PartB:TRK-250 30mg0/4 (0%)0/4 (0%)2/4 (50%)
PartB:TRK-250 60mg0/4 (0%)1/4 (25%)3/4 (75%)
PartB:Pooled Placebo0/6 (0%)0/6 (0%)3/6 (50%)
Most frequent serious events
Most frequent serious events
EventPartA:TRK-250 2mgPartA:TRK-250 10mgPartA:TRK-250 30mgPartA:TRK-250 60mgPartA:Pooled PlaceboPartB:TRK-250 10mgPartB:TRK-250 30mgPartB:TRK-250 60mgPartB:Pooled Placebo
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/30/30/30/30/40/40/41/40/6
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPartA:TRK-250 2mgPartA:TRK-250 10mgPartA:TRK-250 30mgPartA:TRK-250 60mgPartA:Pooled PlaceboPartB:TRK-250 10mgPartB:TRK-250 30mgPartB:TRK-250 60mgPartB:Pooled Placebo
ArrhythmiaCardiac disorders0/30/31/30/30/40/40/40/40/6
Anal fissureGastrointestinal disorders0/30/31/30/30/40/40/40/40/6
DiarrhoeaGastrointestinal disorders1/30/31/30/30/40/40/40/40/6
Alanine aminotransferase increasedInvestigations0/30/31/31/30/40/40/40/40/6
Aspartate aminotransferase increasedInvestigations0/30/30/31/30/40/40/40/40/6
Eosinophil count increasedInvestigations0/30/31/30/30/40/40/40/40/6
Heart rate irregularInvestigations0/30/31/30/30/40/40/40/40/6
CoughRespiratory, thoracic and mediastinal disorders0/30/31/31/30/41/40/40/41/6
DyspnoeaRespiratory, thoracic and mediastinal disorders0/30/31/31/30/40/40/41/40/6
Productive coughRespiratory, thoracic and mediastinal disorders0/30/31/30/31/40/40/40/40/6

Baseline characteristics

Age, Customized
Age, Customized(years)PartA:TRK-250 2mgPartA:TRK-250 10mgPartA:TRK-250 30mgPartA:TRK-250 60mgPartA:Pooled PlaceboPartB:TRK-250 10mgPartB:TRK-250 30mgPartB:TRK-250 60mgPartB:Pooled PlaceboTotal
Age74 (70 to 76)70 (66 to 73)76 (70 to 80)69 (66 to 74)75 (67 to 79)64 (48 to 74)70 (59 to 75)74 (66 to 78)75 (70 to 77)72 (48 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)PartA:TRK-250 2mgPartA:TRK-250 10mgPartA:TRK-250 30mgPartA:TRK-250 60mgPartA:Pooled PlaceboPartB:TRK-250 10mgPartB:TRK-250 30mgPartB:TRK-250 60mgPartB:Pooled PlaceboTotal
Female2111000207
Male12224442627
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PartA:TRK-250 2mgPartA:TRK-250 10mgPartA:TRK-250 30mgPartA:TRK-250 60mgPartA:Pooled PlaceboPartB:TRK-250 10mgPartB:TRK-250 30mgPartB:TRK-250 60mgPartB:Pooled PlaceboTotal
Race — White33234444633
Race — Black or African Black or African American0010000001
08

Study locations

11 sites
  • Pulmonary Associates
    Phoenix, Arizona 85006, United States
  • Cedars-Sinai Medical Center (CSMC) - Women's Guild Lung Institute
    Los Angeles, California 90048, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • Advanced Pulmonary & Sleep Research Institute of Florida
    Daytona Beach, Florida 32117, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Pulmonary Disease Specialists, PA, d/b/a PDS Research. Kissimmee, FL
    Kissimmee, Florida 34741, United States
  • Weill Cornell Medicine
    New York, New York 10021, United States
  • PulmonIx LLC
    Greensboro, North Carolina 27403, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Medical University of South Carolina - Pulmonary & Critical Care Clinical Research Program
    Charleston, South Carolina 29425, United States
  • The University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Apr 2022, 40 months.

Results were first posted in Oct 2023, 1 year 6 months after primary completion.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 40 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2018
First posted
Nov 1, 2018
StartActual
Nov 28, 2018
Primary completionActual
Apr 1, 2022
CompletionActual
Apr 1, 2022
Results first posted
Oct 23, 2023
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03727802
Lead sponsor
Toray Industries, Inc
Responsible party
Sponsor
First posted
Nov 1, 2018
Start date
Nov 28, 2018
Primary completion
Apr 1, 2022
Completion
Apr 1, 2022
Results posted
Oct 23, 2023
Last update
Oct 23, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion